Roundtable: Our Analysts' Most Embarrassing Investing Moments

Worldwide Invest Better Day 9/25/2012

In the lead-up to Sept. 25's Worldwide Invest Better Day, The Motley Fool is reacquainting investors with the basic building blocks of investing.

We've already had an analysts' roundtable on the best investment advice they ever got. And one on the worst investing advice they ever got.

Today, it's time to make them a little uncomfortable. We asked them for their most embarrassing investing moment. Here's what they said.

Morgan Housel: In college, another investor introduced me to a small oil company with a big development project in South America. The bullish pitch made so much sense. You could tell the share price just wasn't reflecting the company's prospects. It was about to ink a massive deal, but the market just didn't seem to care.

I bought in. And not just the company's stock, but call options to juice my exposure. The company eventually signed the South American deal, and it was off to the races. The stock surged and my call options simply exploded, turning into (I'm not making this up) a 15-bagger in less than a year. This was unbelievable for a college kid. I felt invincible.

Well, easy come, easy go. The deal started looking questionable, the economy slowed, management fumbled, oil prices tanked, and so too did the company's stock. I rode my 15-bagger call options all the way down to ... zero. Literally, gone. 

To go from feeling invincible to experiencing a wipeout in a matter of months was the most embarrassing moment I've had as an investor. But it was also the most instructive. I learned so much from the experience that in hindsight I'm actually glad it happened. There is no better way to learn about risk and leverage than to experience it firsthand. 

John Reeves: I really blew it on Eastman Kodak. Just the recollection of how I handled that one is pretty embarrassing. I bought the stock back in 2003, figuring I was getting a solid, all-American company that paid a generous dividend. Sure, there seemed to be challenges with its business, but I just assumed the company would figure it all out.

Shortly after I purchased my shares, the company cut its annual dividend by 72%, while announcing a major shift in its strategy. Kodak intended to move away from its conventional film business, as it concentrated on digital initiatives. I decided to hold on to my shares, lazily thinking the company had the "DNA" to succeed in its new efforts.

I held on for several more years before selling for a loss of around one-third of my original investment. Ultimately, I failed to research this stock sufficiently, and it ended very badly for me. Now, whenever the subject of Kodak's inevitable decline comes up around the water cooler, I try to change the subject.

Buck Hartzell: I remember visiting HGSI (Human Genome Sciences) with a few other Fools. We spent all day meeting with their top scientists and even the CEO, William Haseltine, who apparently had postponed a meeting with the President of the United States to meet with us. Yes, I found that odd, too. It became very obvious to me that I had no business investing in this company. These people were so much smarter than I was and I wasn't convinced they knew what they were doing. I was humbled and embarrassed as we left their facilities. I took a loss on that investment and moved on to other pastures. The only part of that investment that lives on is a coffee mug. I tell each of our children not to break it because it cost us thousands of dollars. Someday I'll explain why that mug was so expensive.

Anders Bylund: This one's a toss-up between two huge errors. I got in on Marvel at $2 a share, way back in 2002. The stock doubled very quickly and I sold my shares, happy to collect a big payday. But that was a short-sighted mistake.

You can imagine how hard I was kicking myself as the stock just kept rising after that. By the time Walt Disney bought Marvel for about $50 per share, I was back in again -- but most of the gains were long gone.

The other black mark on my record comes from OmniVision Technologies (Nasdaq: OVTI  ) , and the wound is still fresh. This time, my head grew too big for my own shoulders.

Last year, I told myself that I knew better than the worrywarts who thought Apple would get its iPhone camera sensors elsewhere. OmniVision's unique chip technology was surely untouchable, or so I thought. By the end of the year, I had been proven wildly wrong and penned a public apology for the mistake.

Matt Thalman: After American Airlines filed for bankruptcy protection and their stock price had already fallen way down, I made a thumbs-up CAPScall on the stock. I had looked through some filings and at how some of the other airlines had done since they went through bankruptcies in recent years. My thinking was that after American cut the fat and restructured some contracts, everything would be fine, and the stock price would rise in the coming years.

I posted a few comments on why I made the pick and then I was enlightened, or extremely embarrassed, you choose. Little did I know that when the majority of companies exit bankruptcy protection, they issue new stock, leaving old shares worthless. The pick is one of my worst, but I have left it active as a reminder of why I play CAPS and the importance of helping other investors.

Jacob Roche: I've had a lot of embarrassing moments as an investor. Like, a lot. But most of them don't make for interesting stories, so I'll tell you about the funniest one.

It was the Jamba (Nasdaq: JMBA  ) 2010 annual shareholders meeting at their headquarters in Emeryville, Calif., a little over an hour's drive from where I live. It was supposed to start at 9 a.m. I hit traffic on the way and got there about 15 minutes late. It was the first shareholders meeting I'd ever been to, so I didn't know quite what to expect and figured it would still be starting up, but instead I walked right in on CEO James White's presentation, some chump kid with messy hair and a nice suit awkwardly paired with sneakers because I think I'm cool, panting from running a couple blocks from where I parked.

White never paused in his remarks, but everyone turned to look at me as I burst into the room and squeezed into the only seat left, where I had about two minutes to catch my breath before his presentation ended, and, after a few minutes of Q&A, the whole meeting was over.

Dan Caplinger: The most embarrassing thing I ever did as an investor was to sell Starbucks (Nasdaq: SBUX  ) near its 2008 lows. Like many other promising stocks, Starbucks suffered in the wake of the financial crisis, and I wanted to take the tax loss, but I'd initially thought I would buy back the shares after the 30-day wash-sale period ended. In the interim, though, I convinced myself that with the Great Recession in full swing, people would refuse to keep paying $4 for coffee drinks. That bad move not only locked in those losses but also cost me a five-bagger.

LouAnn Lofton: Years ago, when I was still figuring out this whole investment thing, still trying to get my bearings, still open to anything and everything from technical analysis to CANSLIM to even day trading, I met a father-son team of futures traders in Austin, Texas. Yes, futures. I can still picture their home office, the dad padding around in his sock feet after kicking off his expensive loafers. In addition to teaching me how to follow little red and green blips on a computer screen (don't ask me what they meant -- I didn't know then and I don't know now) these two offered me an "amazing" deal to get in on the "ground floor" of a company in Houston that would be going public and would "undoubtedly" double or triple or more. I just had to cut a check. So I did.

You know what happened next, right? I never saw that money again. Somehow, things got off track. The "sure thing" wasn't so sure anymore. When I asked for my money back, I was told they'd have to find another "investor" to buy my shares. Um hmm. I'd never even known what business the company was in. Didn't demand to see any financials. Didn't ask any hard questions at all. I just got greedy and saw "easy" dollar signs and jumped. Thankfully, I didn't sacrifice a significant amount of money, but I did learn a significant lesson: There's no such thing as a sure thing, especially when sold to you by a man in socks.

Molly McCluskey: Rolling over a 401(k) to a brokerage account, I was on the phone with a broker and asked a question so dumb that the line went silent. It was the sort of question that showed I had absolutely no idea what I was doing. I had two choices: I could play it off and potentially make some costly mistakes, or I could ask for help and learn. I chose the latter, and realized not only the importance of asking dumb questions, but of having a broker who, awkward silences aside, will never let on just how dumb the question was.

Anand Chokkavelu, CFA: I've got one past and one present.

In 2000, when I was stupidly gambling on stocks based on no more than a new-sounding name and a vague promise of technological domination, I took a job at a telecom start-up. As employee No. 64, I was offered either 10,000 options or an extra $3,000 in salary. I'd heard way too much about the newly minted AOL millionaires to choose the latter. We know how this story ends. At the very least, since we went bust six months later, my choice only cost me $1,500.

I'm not really embarrassed by my decision to take the options (I like feeling like an owner), but I am embarrassed about my general get-rich-quick mind-set and lack of due diligence on investing matters during that period.

Presently, I'm continually humbled by how hard it is to beat the market.

Tim Beyers: I've made many bad calls in articles, no doubt. One of my worst has to be calling Terra Nitrogen a potentially dangerous dividend pick back in 2004. The stock has been a 17-bagger since. Not as bad as failing to buy Apple when I called it cheap in 2003, but still a HUGE miss on my part. Yet neither of these flubs is nearly so bad as buying Amazon.com (Nasdaq: AMZN  ) at more than $70 a share in 1999 on the strength of -- wait for it -- Jeff Bezos appearing on the cover of a favorite business magazine.

Go ahead and laugh. I was the worst kind of novice investor in those days. I'd compound the mistake two years later when I sold in the single digits, missing out on a multibagger recovery. Yet I sold for the right reason, I think: I put our retirement portfolio in cash and spent a full year studying valuation and business analysis, even going so far as to try calculating discounted cash flows on paper (please don't do this unless you want your eyes to bleed). Most of us needn't go to such extreme measures, of course, but embarrassment and an overpowering desire to retire comfortably pushed me to learn as much as I could, and I've been learning ever since.

Eric Volkman: I had just started work in a Czech investment bank and I was eager, really eager, to finally own my first shares. Any shares, it didn't matter. Still a few weeks shy of my first salary, I took a big chunk of my savings at the time -- probably around $100 -- and put in an order for an entire portfolio!

Well, that's if you count one to four shares each of three or four stocks -- I forget the exact numbers -- as a portfolio. I wrote out my order (you did that in 1990s Central Europe) and handed it to the back office girl. She shook her head in disbelief. I left the room and heard the traders spit laughter as they reviewed my measly request. I'm sure I was the running joke among them for the next few days. Ah, well. We all have to start somewhere, right? At least the experience was memorable. And yes, they did fill the order. ("Sweeeeeet! I have three shares of Trade Fairs Brno!")

Chris Baines: Buying Jones Soda for $10.00 at 100 times earnings and then selling it at $22.00 (about 220 times earnings). Yes, I more than doubled my money, but my involvement in the stock was (lowercase) foolish. I made money selling to a bigger idiot and not because of any business acumen. Hence why the stock is trading at $0.34 today. 

The company embarked on a dumb strategy that I should have known better than to endorse (especially at 100 times earnings). After years of hard-won success in the niche skater market, they decided to challenge Coca-Cola and Pepsi in their own backyard: Wal-Mart. Bad idea. They also decided to challenge the twins in the sport stadium market, winning an exclusive contract with Seattle Seahawk's Qwest Stadium. An even worse idea.

What do you suppose happens, dear reader, when a (then) $300 million company decides to challenge Coke and Pepsi on their home turf? Envision a tank running over an ant and you get the picture. This whole experience instilled in me Bruce Greenwald's dictum that growth is meaningless without a durable competitive advantage. Lesson learned. 

Alex Dumortier, CFA: My most embarrassing moment as an investor was buying shares at the flotation of Lastminute.com -- arguably Europe's highest-profile dot.com IPO -- in March 2000. I was planning on flipping the shares on the first day but ended up holding on to them (I don't think the shares were available in my account to trade on the first day, as I recall). I sold them much later at a significant loss in percentage terms, but the allocation was so small to begin with that I was beyond caring at that stage. On reflection, it was a useful lesson in humility and common sense. I had thought I was being clever, seizing the opportunity to make an easy profit; instead, I found myself the proverbial greatest fool buying over-hyped shares at the very top of a multiyear bubble. It was high time to look for a different approach to common stock ownership -- one that emphasized value instead of perpetual motion.

Tim Brugger: OK, this is a painful one, primarily because the wound has yet to heal.

I'm afraid I bought into Stephen Elop and his Nokia turnaround plan, and was more than happy to share my somewhat contrarian thoughts with readers. Though I still hold out hope he can make the transition to smartphones and tablets (I can be slow on the uptake) a successful one, looking back I needed a lot more objectivity, and a lot less subjectivity.

The article in question covered Nokia's new partnership with Microsoft and its smartphone OS; that was in February of this year. At the time, Nokia was on a downward trend (that would quickly become a downward spiral), and boasted what I thought was an "under-valued" stock price of $5.80 a share.

Ahem, sorry about that.

Dan Newman: My first exposure to the financial markets was in an elementary school stock picking game. We formed investing groups, were told we had $100,000 to invest, and selected stocks to see who could earn the most over the school year. Our group's method of stock selection? Opening up the newspaper and tossing a pencil onto it to see which stock it pointed to. Embarrassingly, this method performed the best in the class. While I'm sure other elementary school groups did little true analysis, the fact that we were so successful without any true work made me feel uneasy. This taught me early on that reward without effort is significantly less meaningful than reward with work and reason backing it up. Today, if an investment performs horribly, I'm not embarrassed if I did significant research and had a solid thesis behind choosing it.

Evan Niu, CFA: Jumping into options trading head first before I was fully educated on critically important and complex aspects like pricing. Trading large, short-term, long positions proved to be a terrible mistake, and one that I've only recently recovered fully from. It was an important learning experience, complete with a pricey tuition.

Andrew Marder: The investing world is full of interesting ways to shoot yourself in the gut. As a novice investor, I tried to grab a hold of every conceivable weapon, turn it on myself, and see what happened. For some reason I thought the barrel might spew money all over my chest -- it didn't.

The biggest error I ever made was misunderstanding warrants. It's like a game of chicken where, as time runs out, the car gets harder to steer. As a result, I crashed hard, and the short-term gain I was looking for disappeared. In classic Vegas fashion, I had been up, but I didn't walk away from the table with my chips.

That's a lot of metaphor to say something straightforward, I didn't understand what I was doing, and I was too proud to say so. In the end, it cost me a lot of money, and a lot more pride than I would have lost if I had simply walked away.

Keith Speights: I bought what I knew (or what I thought I knew), and never reexamined the company's business fundamentals. That company was Worldcom. My initial investment doubled -- for a while. When the stock began declining, I held on assuming that the company would continue to be successful as it had been in the past. Was I ever wrong on that one! The stock ended up being worthless. I lost the entire initial investment.

Sean Williams: The one constant about investing is you will undoubtedly make a fool out of yourself at some point. For investors like myself, one time would be an improvement. Take, for example, my optimistic call in 2010 that China-based stocks would vastly outperform U.S. equities over the next three years. I was so confident in this assessment that I created my very own tracking portfolio of 200 Chinese equities in CAPS called UltraChina. Today, UltraChina is the third-worst CAPS portfolio out of 180,000-plus members! Trust me, it takes skill to be that wrong (or so I'd like to think)!

My embarrassing, yet in plain sight, mistake was in assuming that China's corporate regulations would at least be similar to those which we have in the United States. Lo and behold, following a parade of fraud allegations I learned otherwise. I also came away learning and relearning those telltale lessons that if it's too good to be true, it probably is, and that it's rarely a good idea to chase past performance. I let that CAPS tracking portfolio be a constant reminder that there's much more to a company than just a few numbers on a balance sheet and one quarter's worth of earnings results.

Brian Orelli, Ph.D.: I didn't think the likelihood of Dendreon's (Nasdaq: DNDN  ) Provenge working was worth the risk. And, as you probably know, the clinical trial was a success, which eventually led to a Food and Drug Administration approval for the prostate cancer drug.

But that isn't my most embarrassing moment.

My big mistake was flipping to the bull side of the equation. I figured with an approval in hand, Provenge would sell itself. It didn't.

Lesson learned: Drug approvals are necessary for revenue coming in, but they're not sufficient.

Chuck Saletta: Oh -- I've had so many embarrassing investing moments that it's hard to pick just one. Certainly among the top was owning stock in and dueling in favor of Washington Mutual during the subprime mortgage meltdown. I was so blinded by what looked like strong earnings potential and what appeared to be an easily covered dividend that I completely ignored the deteriorating quality of the assets that supposedly underpinned that earnings potential.

While I lost virtually my entire stake as that bank collapsed, I remain thankful that I held steadfast to the principle of diversification that kept me from buying more as the stock kept dropping. I would have sprung an incredible value trap -- and destroyed even more of my limited capital -- had I given into my initial temptation to buy more as it collapsed into its eventual oblivion.

We hope you enjoyed the roundtable and we hope you'll add your embarrassing moments to the comments section below. Also, click on the button below for more on Worldwide Invest Better Day.

 

Roundtable organizer Anand Chokkavelu owns shares of Walt Disney, Microsoft, and Apple. The Motley Fool owns shares of Apple, Walt Disney, Amazon.com, Microsoft Coca-Cola, PepsiCo, Starbucks, and Dendreon. Motley Fool newsletter services have recommended buying shares of Amazon.com, Starbucks, Microsoft, PepsiCo, Coca-Cola, Apple, and Walt Disney. Motley Fool newsletter services have recommended creating a bull call spread position in Apple, writing covered calls on Starbucks, and creating a synthetic covered call position in Microsoft. 

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (10) | Recommend This Article (27)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 14, 2012, at 4:58 PM, Sassy67 wrote:

    I really enjoyed reading the Analysts' most embarrassing investment moments!! It's so good to be able to realize that Analysts are human, too, and can admit their miss-steps! And feel embarrassed about them!

    I am a retired psychotheraist, thus math-challenged. When I retired, my CFO husband (who is a smart guy, honestly) asked me if I would be interested in attending a 2-day Market Trading class with him. I said, "sure, why not?" Ha! Little did I know that I was getting into the biggest and most out-of-my-comfort-zone training of my life!

    That class was in Feb., 2010 and I've been studying Trading every since!! In various programs. Turns out you can be an old dog learning new tricks. The operant word there is learning. Happy Trading! I'm thankful for paper money accounts although I do now trade with a small really money account, too.

    Thanks for reading my story. Most of my friends eyes glaze over when I try to talk about trading.

  • Report this Comment On September 14, 2012, at 5:30 PM, jordanwi wrote:

    Mine friends too, Sassy. I need more Foolish friends. Uncle Joe?

    My ego got in the way last year with short term call options. Also with NFLX this year, doubling down. That would could get worse for me though, time will tell.

    Thankfully, the Fool has taught me a lot and I've steered clear of TOO many foolish mistakes.

  • Report this Comment On September 16, 2012, at 12:54 PM, Risky88 wrote:

    I liked it!

  • Report this Comment On September 16, 2012, at 9:11 PM, lebronz wrote:

    Want to look smart again and gain credibility back again Motley Fewl Staff?

    Increase your FOCUS ON DNDN over the next 3 quarters and write articles that illuminate things about DNDN that other wallstreet articles fail to do!

    Focus on the American Cancer Society facts that:

    *1-2 million men have prostate cancer (pc) in the U.S.

    *271,740 men will/have been diagnosed with pc this year.

    *10% or almost 100,000 men from the 1-2 million man pool have mCRPC (Provenge label).

    *30-35,000 men are newly diagnosed throughout the year with mCRPC (Provenge label).

    *30,000 men die each year from pc.

    *The baby boomer influx over the next 2-7 years only sustains or increases these numbers.

    *The European population of men with PC is similar to the U.S (EU approval of Provenge is up 4 decision next Summer, 2013).

    Don't write articles that surround DNDN in fear, uncertainty, & doubt (FUD).

    Don't apply common stock metrics that investors look at (EPS, etc), revenue/debt or so called balance sheet numbers because wallstreet analysts already focus here. DNDN is still evolving from a R&D biotech to a commercial powerhouse! Cogs are high because who in the world today does what they do>?

    Don't write about a silly lawsuit rumor, because it will be settled by DNDN (if it even gets anywhere), just like how every big pharma settles lawsuits with their insurance or enormous cash coffers.

    Don't spin the NJ plant closing/layoffs as a negative. Corporations close plants all the time! The 2 other, high tech, 155,000 square foot facilities in Seal Beach, CA and Atlanta GA can more than handle U.S. demand and then some (when other immunotherapies come down the pipe like Neuvenge for bladder cancer, etc).

    Don't write about pending bankruptcy claims because DNDN OWNS THE FIRST EVER FDA APPROVED (12 year patent exclusivity under Obamacare), novel, game changing therapeutic immunotherapy cancer vaccine.

    Dying men from prostate cancer want to sustain their quality of life and they can play golf the following weekend after being treated with Provenge.

    Instead, have a Fewlish article or future articles FOCUS on ONE THING.

    FOCUS ON THE SIZE OF THE MARKET FOR PROVENGE (STATISTICS ARE ABOVE)!

    After reading the statistics above again, realize that Dndn is currently treating about 900 men per quarter (3600 men/year) which is $83M in quarterly revenue ($93,000 x 900=$83M).

    Let's ignore the 100K men living with mCRPC. Let's just take the 30,000 men figure that are newly diagnosed with mCRPC throughout a year and divide it by 4.

    That equates to 7500 men newly diagnosed each quarter with mCRPC.

    Dndn is only treating about 900 men out of the 7500 men newly diagnosed with mCRPC each quarter. That's less then 1/7th of the available mCRPC population.

    Ok, you can close your mouth Fewls.

    Dndn's current annual treatment rate is 3600 (900x4) men.

    Remember, 7500 men are newly diagnosed w/ mCRPC each quarter.

    And remember, we're not including those 100,000 men already living with mCRPC!!

    Okay, you can sit down now Fewls.

    Here are Provenge quarterly sales since launch back in April, 2010 when the FDA finally approved it. How does this look like for sales growth to you>>?

    Q2/10: $2.8M

    Q3/10: $20.2M

    Q4/10: $25M

    2010 Revenue Total: $48M

    Q1/11: $28M

    Q2/11: $49.6M

    Q3/11: $64.3M

    Q4/11: $77M

    2011 Revenue Total: $220M

    Q1/12: $82M

    Q2/12: $80M

    Q3/12: TBD

    Q4/12: TBD

    2012 Revenue Total So Far: $162M

    Total Revenue Since Launch: $430M (Only 4,623 men treated with Provenge so far;

    TREATING JUST 4,623 MEN SINCE LAUNCH 2.5 YEARS AGO BARELY MAKES A DENT IN THE OVERALL U.S. mCRPC market!

    I KNOW IT, MY MOM KNOWS IT, AND YOU FEWLS KNOW IT!

    SO WRITE ABOUT IT!

    ARE YOU REALLY GOING TO WRITE ABOUT THE 2 MILLION DECREASE FROM Q1 TO Q2 THIS YEAR?

    ARE YOU REALLY GOING TO WRITE ABOUT THE 6 MILLION SHORTFALL FROM MANIPULATED CONSENSUS ESTIMATE OF 86 MILLION FOR Q2?

    Finally Fewls, ignore the threats of competion (Zytiga, MDV3100) because, unfortunately, there are more than enough men to go around to all players in the PC space. Wallstreet & their institutional clients (currently own 61% of dndn outstanding shares) want you to believe that competition will drive down Provenge sales.

    There are 3 reasons why this is bogus!

    First, ethical doctors (urologists/oncologists) will treat dying patients with their interests at heart, not the competition.

    Second, doctors will "sequence" the available therapies to extend survival of the dying patient to the max!

    And third, there is a little bitty incentive for doctors to infuse Provenge. It's only $5500 per patient ;o)

    Get ready Fewls!

    Wallstreet is manipulating/shorting this stock over time to keep prices depressed the remainder of 2012 (short to distort tactic) to get your shares.. if you have any.

    CEO JJ is working with the LARGE SHAREHOLDERS too to keep expectational guidance modest.

    The CEO philosophy is called "Underpromise to Overdeliver"!

    Are you on wallstreets side or retailz side Fewls?

    How bout telling us to hold dndn shares tightly (don't set limits up or down).

    Tell us that Dndn will become the next Celgene beginning late next Summer when CEO Johnson surprises, and the shorts cover (not because they have to cover, but to simply support the surprise). You and I know that $500B to $1T large institutions/hedge funds don't HAVE TO COVER SHORT SHARES! Read up on the "short to distort" tactic used by tutes to depress stock prices over time and wear down retail to SELL.

    Dndn soon will become the next Celgene back when they launched Revlimid in their initial drug launch heyday!

    Cheers Fewls!

    Labronz Thee Dendreonite!

  • Report this Comment On September 17, 2012, at 11:06 AM, TMFMileHigh wrote:

    @Labronz,

    Good stuff. I like how passionate you are about DNDN.

    What I don't understand is why are long this stock in CAPS? Why not join us in putting your rep on the line?

    Foolish best,

    Tim

    --

    Tim Beyers

    TMFMileHigh, Motley Fool Rule Breakers Analyst, Supernova Odyssey I Portfolio Contributor

    Web: http://timbeyers.me

  • Report this Comment On September 17, 2012, at 1:17 PM, TMFMileHigh wrote:

    Well, that was dumb. Instead of this:

    >>What I don't understand is why are long this stock in CAPS?

    I meant to write:

    >>What I don't understand is why **aren't you** long this stock in CAPS?

    My apologies and Foolish best,

    Tim

    --

    Tim Beyers

    TMFMileHigh, Motley Fool Rule Breakers Analyst, Supernova Odyssey I Portfolio Contributor

    Web: http://timbeyers.me

  • Report this Comment On September 17, 2012, at 2:35 PM, lebronz wrote:

    http://www.fool.com/investing/general/2012/09/15/heres-what-...

    Hey Tim, thanks!

    You can read my revised comments that I've just placed in your Fewl colleague Selena's article (link above).

    She talks about DNDN in the negative and mis-represents facts about Tudor Investment Corporation! They sold dndn in Q1 not Q2

    I'm not sure why I'm not long dndn in CAPS. Not sure it will really impact what DNDN is trying to do for men in the U.S. and the ROW.

    There goal is to treat as many men dying from prostate cancer with an FDA approved immunotherapy vaccine and they really don't need falsehoods spread about them succeeding in their effort because the stock price is being manipulated by mega wealthy hedgies/institutions who want shares all to themselves.

    I've read all your Foolish colleagues articles on DNDN and hope my comment summaries help them in the future. I started with Ms Selena (link above).

    I also think Mr Brian Orelli is hopelessly lost on his research & videos concerning DNDN. He's great on camera though!

    good luck to you!

    L

  • Report this Comment On September 17, 2012, at 3:04 PM, lebronz wrote:

    Sorry,, I meant Dave Williamson is lost on DNDN!

  • Report this Comment On September 18, 2012, at 4:02 PM, Darwood11 wrote:

    Nice article.

    One of my favorite embarrassments involved my spouse, who was not an investor, but is learning and will probably do better than I do in the long run.

    Back in 2000, she kept telling me she wanted to buy some gold. In fact, in one of my annual letters to extended family, I told them that what she wanted was "Krugerrands for Christmas." I didn't buy her any.

    2000 was, I think, the most recent bottom for gold. About once a year I get reminded that I didn't buy gold back then.

  • Report this Comment On October 30, 2012, at 2:37 AM, 650nm wrote:

    I'm still wondering what question it was TMFAlaska had asked that was so dumb. Everyone else shared pretty specific details, what about yours, Molly?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2017556, ~/Articles/ArticleHandler.aspx, 9/1/2014 8:30:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement